TRPV4 mediates hypotonicity-induced ATP release by the thick ascending limb.
Extracellular ATP is an autocrine/paracrine factor that regulates renal function. Transient receptor potential vanilloid (TRPV) 4 is a cation channel that mediates release of autocrine/paracrine factors by acting as an osmosensor. The renal medulla, and therefore the thick ascending limb, is exposed to osmotic stress. We hypothesize that reduced osmolality stimulates ATP release from the thick ascending limb via transient receptor potential vanilloid (TRPV) 4 activation. We measured ATP release by medullary thick ascending limb suspensions after reducing bath osmolality from 350 to 323 mosmol/kgH2O, using the luciferin-luciferase assay. Decreasing osmolality stimulated ATP release compared with control (38.9+/-7.2 vs. 2.4+/-1.0 pmol/mg protein; n=6, P<0.01). To examine the role of TRPV4, we used 1) Ca-free solutions, 2) a TRPV4 inhibitor, 3) small interfering (si) RNA against TRPV4, and 4) a TRPV4 activator. Removal of Ca completely blocked osmolality-induced ATP release (42.2+/-5.9 vs. 2.6+/-1.5 pmol/mg protein; n=6, P<0.01). In the presence of the TRPV4-selective inhibitor ruthenium red, osmolality-induced ATP release was blocked by 73% (56.4+/-19.9 vs. 8.8+/-2.3 pmol/mg protein; n=6; P<0.03). In vivo treatment of thick ascending limbs with siRNA against TRPV4 decreased osmolality-induced ATP release by 62% (31.5+/-3.4 vs. 12.4+/-1.1 pmol/mg protein; n=6; P<0.01), while reducing TRPV4 expression by 74% compared with the nontreated kidney. Treatment with scrambled siRNA did not affect TRPV4 expression and/or osmolality-induced ATP release. Finally, in the absence of changes in osmolality, the specific TRPV4 agonist 4alpha-PDD increased ATP release (3.6+/-0.9 vs. 25.4+/-7.4 pmol/mg protein; n=6; P<0.04). We concluded that decreases in osmolality stimulate ATP release by thick ascending limbs and this effect is mediated by TRPV4 activation.
Silva
Guillermo B
GB
Division of Hypertension and Vascular Research, Henry Ford Hospital, and Department of Physiology, School of Medicine, Wayne State University, 2799 W. Grand Blvd., Detroit, MI 48202, USA.
Garvin
Jeffrey L
JL
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D015870:Gene Expression / Q000502:physiology; D007038:Hypotonic Solutions / Q000494:pharmacology; D008138:Loop of Henle / Q000378:metabolism*; D008297:Male; D034741:RNA, Small Interfering; D051381:Rats; D017207:Rats, Sprague-Dawley; D012430:Ruthenium Red / Q000494:pharmacology; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D014882:Water-Electrolyte Balance / Q000502:physiology*
D002614:Chelating Agents; D007038:Hypotonic Solutions; D034741:RNA, Small Interfering; D050916:TRPV Cation Channels; C486577:Trpv4 protein, rat; D012430:Ruthenium Red; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D004533:Egtazic Acid; D000255:Adenosine Triphosphate; D002118:Calcium